You are here: Industry Insights > GSK

News List

GSK’s Nucala approved to treat chronic rhinosinusitis with nasal polyps pharmatimes
August 02, 2021
GlaxoSmithKline’s (GSK) interleukin-5 (IL-5) inhibitor has received approval from the US Food and Drug Administration (FDA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps firstwordpharma
July 30, 2021
GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps.
GSK and Vir enter supply deal with European Commission for Covid-19 drug pharmaceutical-technology
July 29, 2021
GlaxoSmithKline and Vir Biotechnology have entered a joint procurement agreement with the European Commission (EC) to deliver up to 220,000 doses of the companies’ experimental drug, sotrovimab, to treat Covid-19.
US FDA approves Shingrix to prevent shingles in immuno-compromised adults expresspharma
July 28, 2021
Shingrix, a non-live, recombinant sub-unit adjuvanted vaccine, given intramuscularly in two doses, was initially approved by FDA in 2017 for the prevention of shingles in adults 50 years of age or older.
Shingrix Approved for Shingles Prevention in Immunocompromised Adults americanpharmaceuticalreview
July 27, 2021
GlaxoSmithKline plc announced that the US FDA has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to ...
GSK Announces Positive Headline Results from Five Phase 3 Studies of Daprodustat for Patients with Anemia due to Chronic Kidney Disease drugs
July 23, 2021
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase
EU begins real-time review of Sanofi-GSK COVID-19 vaccine expresspharma
July 22, 2021
The decision to start the "rolling review" of the vaccine, Vidprevtyn, was based on preliminary results from lab studies and early-stage clinical trials in adults, the European Medicines Agency (EMA) said.
GSK to build $549m biotech hub in Stevenage, UK pharmaceutical-technology
July 20, 2021
GlaxoSmithKline (GSK) has plans to open an approximately $549m (£400m) biotechnology campus in Stevenage, UK, which would possibly create up to 5,000 skilled jobs in the coming five to ten years.
COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them prnasia
July 09, 2021
Yesterday sees the launch of Let's treat it right, a major new health education campaign designed to bridge a knowledge gap and unlock health benefits for millions of people2.
Sanofi, GSK get approval for Phase 3 COVID-19 vaccine trial in India expresspharma
July 09, 2021
In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original virus strain (D.614), while a second stage will evaluate a second formulation targeting the Beta variant (B.1.351).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page